Venmax Drugs

Why is Venmax Drugs & Pharmaceuticals Ltd falling/rising?

As of 04-Sep, Venmax Drugs & Pharmaceuticals Ltd's stock price has risen to Rs 14.75, reflecting a 4.46% increase. Despite recent gains, the stock remains below its moving averages and has experienced significant declines over the past year, indicating potential concerns about the sustainability of this upward trend.

As of 04-Sep, Venmax Drugs & Pharmaceuticals Ltd is experiencing a rise in its stock price, currently at Rs 14.75, which reflects an increase of Rs 0.63 or 4.46%. This upward movement is notable as the stock has outperformed its sector by 8.74% today and has shown consecutive gains over the last two days, accumulating a total return of 9.76% during this period. <BR><BR>The stock opened with a significant gain of 6.16% today and reached an intraday high of Rs 15.3, indicating strong buying interest. Despite the overall negative performance over longer periods, such as a 40.88% decline year-to-date and a 43.27% drop over the past year, the recent short-term performance suggests a positive shift in sentiment. <BR><BR>However, it is important to note that the stock is trading below its moving averages across various timeframes, indicating a longer-term bearish trend. Additionally, there has been a decrease in investor participation, with delivery volume falling by 13.3% compared to the five-day average. This could suggest that while the stock is currently rising, there may be underlying concerns regarding its sustainability. <BR><BR>Overall, the recent price increase can be attributed to short-term trading activity and market sentiment, despite the broader context of declining performance over the past year.

Which are the latest news on Venmax Drugs?

Who are in the management team of Venmax Drugs?

The management team of Venmax Drugs includes Rajkumar Rai (Managing Director), N Krishnaiah (Non Executive Director), A Ramakrishnaiah (Non Executive Independent Director), N V Narender (Chairman), and Gali Satya Venkata Divya Jyothi (Non Executive Independent Director).

The management team of Venmax Drugs includes the following individuals:<BR><BR>1. **Rajkumar Rai** - Managing Director<BR>2. **N Krishnaiah** - Non Executive Director<BR>3. **A Ramakrishnaiah** - Non Executive Independent Director<BR>4. **N V Narender** - Chairman<BR>5. **Gali Satya Venkata Divya Jyothi** - Non Executive Independent Director<BR><BR>If you need more details about their roles or the company, feel free to ask!

What does Venmax Drugs do?

Venmax Drugs & Pharmaceuticals Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, incorporated in 1998 and known for its recent quarterly net sales of 2 Cr and net profit of 0 Cr as of June 2026. The company has a market cap of INR 23 Cr and key financial metrics include a P/E ratio of 82.00 and a return on equity of 1.87%.

Overview:<BR>Venmax Drugs & Pharmaceuticals Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>The company was initially incorporated in 1998 under the name "Yenkay Medico Private Limited." It changed its name to "Yenkey Drugs & Pharmaceuticals Private Limited" in 1995 and became a Public Limited Company on February 3, 1995. The final name change to "Venmax Drugs & Pharmaceuticals Limited" occurred on April 13, 2009. The most recent quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 2 Cr (Quarterly Results - Jun 2026)<BR>- Net Profit: 0 Cr (Quarterly Results - Jun 2026)<BR>- Market Cap: INR 23 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 82.00<BR>- Industry P/E: 37<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.04<BR>- Return on Equity: 1.87%<BR>- Price to Book: 1.54<BR><BR>Contact Details:<BR>Address: H.No 1-140 Rajeswari Warehouse, Kompally Quthbullapur Hyderabad Telangana : 500014<BR>Email: venmaxdrugs@gmail.com<BR>Website: http://www.venmaxdrugs.com

Who are the peers of the Venmax Drugs?

Venmax Drugs' peers include Guj. Terce Labs, Medi Caps, Cian Healthcare, Welcure Drugs, Ishita Drugs, Centuple Global, Shree Ganesh Bio, Colinz Labs, and Medicamen Organ, with varying management risks and growth rates. Cian Healthcare leads in 1-year returns at 252.28%, while Venmax Drugs has a return of -50.74%.

Peers: The peers of Venmax Drugs are Guj. Terce Labs., Medi Caps, Cian Healthcare, Welcure Drugs, Ishita Drugs, Centuple Global, Shree Ganesh Bio, Colinz Labs, Medicamen Organ.<BR><BR>Quality Snapshot: Below Average management risk is observed at Guj. Terce Labs., Medi Caps, Cian Healthcare, Ishita Drugs, Shree Ganesh Bio, Colinz Labs, and Medicamen Organ. Average management risk is found at Welcure Drugs and Venmax Drugs, while Good management risk is noted at Centuple Global. Growth is Average at Venmax Drugs, Average at Guj. Terce Labs., and Below Average at Medi Caps, Cian Healthcare, Ishita Drugs, Shree Ganesh Bio, and Medicamen Organ, while Good growth is seen at Centuple Global. Capital Structure is Good at Medi Caps, Welcure Drugs, Ishita Drugs, Shree Ganesh Bio, and Colinz Labs, while Below Average is noted at Venmax Drugs, Guj. Terce Labs., Cian Healthcare, and Medicamen Organ.<BR><BR>Return Snapshot: Cian Healthcare has the highest 1-year return at 252.28%, while Welcure Drugs has the lowest at -72.73%. Venmax Drugs’ 1-year return of -50.74% is better than Welcure Drugs but worse than Cian Healthcare. Additionally, the six-month returns are negative for Guj. Terce Labs., Welcure Drugs, Venmax Drugs, Ishita Drugs, Centuple Global, Shree Ganesh Bio, and Medicamen Organ.

How big is Venmax Drugs?

As of 31st August, Venmax Drugs & Pharmaceuticals Ltd has a market capitalization of 23.00 Cr, with recent net sales of 9.29 Cr and a net profit of 0.28 Cr. The balance sheet for March 2025 shows shareholder's funds of 4.41 Cr and total assets of 5.17 Cr.

As of 31st August, Venmax Drugs & Pharmaceuticals Ltd has a market capitalization of 23.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Venmax Drugs reported Net Sales of 9.29 Cr and a Net Profit of 0.28 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, showing Shareholder's Funds of 4.41 Cr and Total Assets of 5.17 Cr.

Should I buy, sell or hold Venmax Drugs & Pharmaceuticals Ltd?

Are Venmax Drugs & Pharmaceuticals Ltd latest results good or bad?

Venmax Drugs & Pharmaceuticals Ltd's latest results show impressive revenue growth of 1,093.94% year-over-year, but profitability is a concern with a net profit decline of 85.90% and low operating margins. Additionally, a significant drop in promoter shareholding raises questions about the company's financial health and sustainability.

The latest results for Venmax Drugs & Pharmaceuticals Ltd present a mixed picture. On one hand, the company has achieved remarkable revenue growth, with net sales soaring by 1,093.94% year-over-year, increasing from ₹0.33 crores to ₹3.94 crores in Q4 FY26. This significant top-line expansion is a positive indicator of the company's ability to scale its operations.<BR><BR>However, the profitability aspect raises concerns. The net profit for the quarter was only ₹0.11 crores, which represents a staggering decline of 85.90% compared to the same quarter last year. The operating margin is also very low at just 0.25%, indicating that the company is struggling to convert its revenue into profit effectively. Additionally, a substantial portion of the operating profit (90%) came from other income rather than core pharmaceutical operations, which questions the sustainability of its earnings.<BR><BR>The company's financial health is further complicated by a significant drop in promoter shareholding, which has decreased from 23.13% to 13.80% over the past year, signaling a lack of confidence from insiders. Overall, while the revenue growth is impressive, the declining profitability, reliance on non-operational income, and promoter confidence issues suggest that the results are more concerning than positive.

When is the next results date for Venmax Drugs & Pharmaceuticals Ltd?

The next results date for Venmax Drugs & Pharmaceuticals Ltd is 14 May 2026.

The next results date for Venmax Drugs & Pharmaceuticals Ltd is scheduled for 14 May 2026.

How has been the historical performance of Venmax Drugs?

Venmax Drugs has experienced significant fluctuations in financial performance, with net sales increasing to 0.81 Cr in March 2025 from 0.00 Cr in the previous year, but overall profitability declined, resulting in a negative profit after tax of -0.01 Cr. Despite growth in sales and total assets, the company faces challenges in maintaining profitability due to rising expenditures and liabilities.

Answer:<BR>The historical performance of Venmax Drugs shows significant fluctuations in its financial metrics over the years, particularly in net sales, operating profit, and overall profitability.<BR><BR>Breakdown:<BR>Venmax Drugs reported net sales of 0.81 Cr in March 2025, a notable increase from 0.00 Cr in March 2024, but still below the 2.55 Cr recorded in March 2015. The total operating income followed a similar trend, reaching 0.81 Cr in March 2025, compared to 0.00 Cr in the previous year. However, total expenditure surged to 1.86 Cr in March 2025, up from 0.10 Cr in March 2024, leading to an operating profit (PBDIT) of 0.00 Cr in March 2025, a decline from 0.10 Cr in March 2024. The profit before tax was slightly negative at -0.01 Cr in March 2025, contrasting with a profit of 0.09 Cr in March 2024. Consequently, the profit after tax also fell to -0.01 Cr in March 2025 from 0.06 Cr in March 2024. The company's total assets increased to 5.17 Cr in March 2025 from 0.08 Cr in March 2024, while total liabilities also rose to 5.17 Cr in March 2025, reflecting a significant increase in short-term borrowings. The cash flow from operating activities was negative at -2.00 Cr in March 2025, although the net cash inflow was positive at 2.00 Cr due to financing activities. Overall, the financial performance of Venmax Drugs indicates challenges in maintaining profitability despite some growth in sales and assets.

Who are the top shareholders of the Venmax Drugs?

The top shareholders of Venmax Drugs are Venkat Narender Nuka with 17.69%, and Percy Homi Italia with 8.9%. Individual investors own 65.24% of the company, with no institutional holdings or pledged promoter shares.

The top shareholders of Venmax Drugs include Venkat Narender Nuka, who holds the highest promoter stake at 17.69%. The highest public shareholder is Percy Homi Italia, with a holding of 8.9%. Additionally, individual investors collectively own 65.24% of the company. Notably, there are no institutional holdings from mutual funds or foreign institutional investors, and there are no pledged promoter holdings.

Is Venmax Drugs overvalued or undervalued?

As of December 2, 2024, Venmax Drugs is considered a risky investment due to its overvaluation, reflected in a PE ratio of -12.77, an EV to EBITDA of -9.85, a ROCE of -53.54%, and a recent stock decline of 10.22%, contrasting with the Sensex's 3.83% increase.

As of 2 December 2024, the valuation grade for Venmax Drugs has moved from does not qualify to risky. Based on the analysis, the company is considered overvalued. Key ratios include a PE ratio of -12.77, an EV to EBITDA of -9.85, and a ROCE of -53.54%. <BR><BR>In comparison to its peers, Venmax Drugs has a significantly lower PE ratio than Sun Pharma, which stands at 35.25, and a much less favorable EV to EBITDA ratio compared to Cipla's 15.93. The company's negative performance metrics, alongside its recent stock decline of 10.22% over the past month against a 3.83% increase in the Sensex, further reinforce the notion that Venmax Drugs is not a sound investment at its current valuation.

What is the technical trend for Venmax Drugs?

As of April 1, 2025, Venmax Drugs shows a mildly bullish trend, supported by daily moving averages, but mixed signals from weekly and monthly indicators suggest a cautious outlook.

As of 1 April 2025, the technical trend for Venmax Drugs has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by the daily moving averages indicating a positive trend. However, the weekly MACD and KST are mildly bearish, suggesting some caution. The monthly MACD remains bullish, but the monthly RSI is bearish, indicating weakness in momentum. Overall, the mixed signals from various time frames suggest a cautious outlook despite the mildly bullish trend.

Has Venmax Drugs declared dividend?

No Dividend History Available